Here you will find financial news and reports from APONTIS PHARMA as well as other publications relevant to the capital market.

APONTIS PHARMA publications in detail and up to date

developAd-hoc-Releases

  • There are no current ad hoc releases available.

  • 2021‑05‑06 | DGAP-Ad-hoc

    APONTIS PHARMA AG sets placement price for its IPO at EUR 19.00 per share

    APONTIS PHARMA AG / Key word(s): IPO APONTIS PHARMA AG sets placement price for its IPO at EUR 19.00 per share 06-May-2021 / 20:07 CET/CEST Disclosure of a...

    Read more...

developCorporate News

  • 2022‑08‑11 | DGAP-News

    APONTIS PHARMA expands profitable positioning in first half of 2022 – full-year forecast confirmed

    DGAP-News: APONTIS PHARMA AG / Key word(s): Half Year Report/Half Year Results APONTIS PHARMA expands profitable positioning in first half of 2022 – full-year forecast confirmed Read more...

    2022‑07‑19 | DGAP-News

    APONTIS PHARMA and Midas Pharma agree on further development partnership for the market launch of a ...

    DGAP-News: APONTIS PHARMA AG / Key word(s): Alliance/Market launch APONTIS PHARMA and Midas Pharma agree on further development partnership for the market launch of a single pill with pan-European i...

    Read more...
    2022‑07‑06 | DGAP-News

    APONTIS PHARMA rolls out new Single Pill for secondary prophylaxis

    DGAP-News: APONTIS PHARMA AG / Key word(s): Market launch APONTIS PHARMA rolls out new Single Pill for secondary prophylaxis 06.07.2022 / 07:30 ...

    Read more...
    2022‑06‑23 | DGAP-News

    APONTIS PHARMA AG: Notice according to Article 2 paragraph 1 of Delegated Regulation (EU) 2016/1052

    DGAP-News: APONTIS PHARMA AG / Key word(s): Share Buyback APONTIS PHARMA AG: Notice according to Article 2 paragraph 1 of Delegated Regulation (EU) 2016/1052 2...

    Read more...
    2022‑05‑25 | DGAP-News

    APONTIS PHARMA launches two new single pills - medium-term revenue potential of EUR 8.2 million

    DGAP-News: APONTIS PHARMA AG / Key word(s): Product Launch APONTIS PHARMA launches two new single pills - medium-term revenue potential of EUR 8.2 million 25.0...

    Read more...
    2022‑05‑12 | DGAP-News

    APONTIS PHARMA holds Annual General Meeting 2022 - shareholders approve all agenda items with large ...

    DGAP-News: APONTIS PHARMA AG / Key word(s): AGM/EGM APONTIS PHARMA holds Annual General Meeting 2022 - shareholders approve all agenda items with large majorities Read more...

    2022‑05‑10 | DGAP-News

    APONTIS PHARMA continues strong profitable growth in Q1 2022

    DGAP-News: APONTIS PHARMA AG / Key word(s): Quarterly / Interim Statement APONTIS PHARMA continues strong profitable growth in Q1 2022 10.05.2022 / 07:30 Read more...

    2022‑05‑05 | DGAP-News

    APONTIS PHARMA and Develco Pharma enter development partnership for launch of two Single Pills with ...

    DGAP-News: APONTIS PHARMA AG / Key word(s): Product Launch APONTIS PHARMA and Develco Pharma enter development partnership for launch of two Single Pills with pan-European intellectual property rights...

    Read more...
    2022‑04‑20 | DGAP-News

    APONTIS PHARMA: START study published in scientific journal - Cost reduction in the treatment of car...

    DGAP-News: APONTIS PHARMA AG / Key word(s): Scientific publication APONTIS PHARMA: START study published in scientific journal - Cost reduction in the treatment of cardiovascular patients by Single Pi...

    Read more...
    2022‑03‑16 | DGAP-News

    APONTIS PHARMA: START study published in scientific journal - Lower incidence of cardiovascular even...

    DGAP-News: APONTIS PHARMA AG / Key word(s): Scientific publication 16.03.2022 / 07:30 The issuer is solely responsible for the content of this announc...

    Read more...
    2022‑03‑15 | DGAP-News

    APONTIS PHARMA AG: Notice according to Article 2 paragraph 1 of Delegated Regulation (EU) 2016/1052

    DGAP-News: APONTIS PHARMA AG / Key word(s): Share Buyback 15.03.2022 / 07:30 The issuer is solely responsible for the content of this announcement. Read more...

    2022‑03‑08 | DGAP-News

    APONTIS PHARMA and AstraZeneca extend strategic sales cooperation

    DGAP-News: APONTIS PHARMA AG / Key word(s): Alliance 08.03.2022 / 07:30 The issuer is solely responsible for the content of this announcement. ...

    Read more...
    2022‑03‑03 | DGAP-News

    APONTIS PHARMA reports successful financial year 2021 - Single Pills as growth driver

    DGAP-News: APONTIS PHARMA AG / Key word(s): Preliminary Results/Annual Results 03.03.2022 / 07:30 The issuer is solely responsible for the content of ...

    Read more...
  • 2021‑12‑16 | DGAP-News

    APONTIS PHARMA strengthens management for future growth: Thomas Zimmermann appointed new CFO

    DGAP-News: APONTIS PHARMA AG / Key word(s): Personnel 16.12.2021 / 07:30 The issuer is solely responsible for the content of this announcement. ...

    Read more...
    2021‑12‑14 | DGAP-News

    APONTIS PHARMA and Midas Pharma announce development partnership to launch Single Pill with pan-Euro...

    DGAP-News: APONTIS PHARMA AG / Key word(s): Product Launch/Alliance 14.12.2021 / 07:30 The issuer is solely responsible for the content of this announ...

    Read more...
    2021‑11‑18 | DGAP-News

    APONTIS PHARMA grows significantly faster than the overall market in the nine-month period 2021 - Re...

    DGAP-News: APONTIS PHARMA AG / Key word(s): Quarterly / Interim Statement/9 Month figures 18.11.2021 / 07:30 The issuer is solely responsible for the ...

    Read more...
    2021‑10‑26 | DGAP-News

    APONTIS PHARMA announces market launch of new Single Pill

    DGAP-News: APONTIS PHARMA AG / Key word(s): Product Launch 26.10.2021 / 07:30 The issuer is solely responsible for the content of this announcement. Read more...

    2021‑09‑14 | DGAP-News

    APONTIS PHARMA announces launch of new Single Pill for more efficient treatment of hypertension and ...

    DGAP-News: APONTIS PHARMA AG / Key word(s): Product Launch 14.09.2021 / 07:30 The issuer is solely responsible for the content of this announcement. Read more...

    2021‑08‑11 | DGAP-News

    APONTIS PHARMA builds on strong position and profitability in first half of 2021 - preliminary figur...

    DGAP-News: APONTIS PHARMA AG / Key word(s): Half Year Results/Half Year Report 11.08.2021 / 07:30 The issuer is solely responsible for the content of ...

    Read more...
    2021‑07‑28 | DGAP-News

    APONTIS PHARMA reports accelerated growth in first half of 2021 - Single Pill revenues +83% to EUR 1...

    DGAP-News: APONTIS PHARMA AG / Key word(s): Preliminary Results/Half Year Results 28.07.2021 / 07:30 The issuer is solely responsible for the content ...

    Read more...
    2021‑07‑12 | DGAP-News

    APONTIS PHARMA marks further success in the roll-out of Single Pill therapy

    DGAP-News: APONTIS PHARMA AG / Key word(s): Alliance 12.07.2021 / 07:30 The issuer is solely responsible for the content of this announcement. ...

    Read more...
    2021‑06‑18 | DGAP-News

    APONTIS PHARMA AG: Initial studies confirm that the share has a price potential of between 77% and 1...

    DGAP-News: APONTIS PHARMA AG / Key word(s): Research Update 18.06.2021 / 07:30 The issuer is solely responsible for the content of this announcement.<...

    Read more...
    2021‑06‑10 | DGAP-News

    APONTIS PHARMA AG: Post-Stabilisation disclosure - Partial exercise of the Greenshoe Option

    DGAP-News: APONTIS PHARMA AG / Key word(s): Miscellaneous 10.06.2021 / 21:23 The issuer is solely responsible for the content of this announcement. Read more...

    2021‑06‑10 | DGAP-News

    APONTIS PHARMA AG: Notification on the implementation of stabilization measures

    DGAP-News: APONTIS PHARMA AG / Key word(s): Miscellaneous 10.06.2021 / 21:20 The issuer is solely responsible for the content of this announcement. Read more...

    2021‑05‑28 | DGAP-News

    APONTIS PHARMA AG: Notification on the implementation of stabilization measures

    DGAP-News: APONTIS PHARMA AG / Key word(s): Miscellaneous 28.05.2021 / 20:05 The issuer is solely responsible for the content of this announcement. Read more...

    2021‑05‑20 | DGAP-News

    APONTIS PHARMA AG Trading Update: Strong revenues and earnings growth with Single Pills continues i...

    DGAP-News: APONTIS PHARMA AG / Key word(s): Quarterly / Interim Statement 20.05.2021 / 07:30 The issuer is solely responsible for the content of this ...

    Read more...
    2021‑05‑19 | DGAP-News

    APONTIS PHARMA AG: Notification on the implementation of stabilization measures

    DGAP-News: APONTIS PHARMA AG / Key word(s): Miscellaneous 19.05.2021 / 20:23 The issuer is solely responsible for the content of this announcement. Read more...

    2021‑05‑14 | EQS-News

    Apontis Pharma (APPH): Initiation - A phoenix rises

    Edison Investment Research Limited 14-May-2021 / 07:00 GMT/BST

    Read more...

developFinancial Reports

  • 2022‑08‑11

    Half-yearly financial statements 2022

    PDF
    2022‑03‑30

    Annual financial statements 2021

    PDF
    2022‑03‑30

    Declaration of Compliance 2021 (German only)

    PDF
    2022‑03‑30

    Einzelabschluss 2021 (german only)

    PDF
  • 2021‑08‑11

    Half-yearly financial statements 2021

    PDF
    2021‑06‑28

    Annual financial statements 2020

    PDF

developCompany Presentation & Webcast

  • 2022‑08‑11

    H122 Results Presentation

    PDF
    2022‑05‑10

    3M22 Earnings Call

    MP4
    2022‑05‑10

    3M22 Unaudited Results

    PDF
    2022‑03‑03

    FY21 Preliminary Results

    PDF
  • 2021‑11‑18

    9M Results Presentation

    PDF
    2021‑08‑11

    H1 Results Presentation

    PDF

developFinancial Calendar

  • Mar 03, 2022

    Preliminary (unaudited) annual figures 2021 / Earnings Call

    Mar 30, 2022

    Annual Report 2021

    May, 2022

    MKK – Münchner Kapitalmarkt Konferenz (May 3 - 4, 2022)
    Munich

    May 10, 2022

    Interim Statement 3M/Q1 2022 / Earnings Call

    May 12, 2022

    Annual General Meeting
    Dusseldorf

    May 18, 2022

    PLATOW Euro Finance Small Cap Conference
    Frankfurt (Main)

    Jun 24, 2022

    Warburg Highlights Conference
    Hamburg

    Jun 29, 2022

    34. Prior Kapitalmarktkonferenz
    Frankfurt (Main)

    Aug 11, 2022

    Half-year Report 2022 / Earnings Call

    Aug 25, 2022

    Hamburger Investorentag (HIT)
    Hamburg

    Sep 05, 2022

    German Fall Conference
    Frankfurt (Main)

    October, 2022

    CF&B European MidCap Event
    Paris

    Nov 10, 2022

    Interim Statement 9M/Q3 2022 / Earnings Call

    Nov 28, 2022

    EKF Deutsches Eigenkapitalforum
    Frankfurt (Main)

  • February, 2021

    2020 Annual Report

    April, 2021

    Annual General Meeting 2021

    Jul 28, 2021

    Preliminary half-year figures

    Aug 11, 2021

    Publication of half-year financial statements / Conference call 14.00 CST

    Aug 26, 2021

    Hamburger Investorentag (HIT)
    Hamburg

    September, 2021

    Roadshow

    Sep 06, 2021

    Equity Forum German Fall Conference
    Frankfurt/Main

    Nov 18, 2021

    Quarterly Statement 9M 2021

    Nov 22, 2021

    German Equity Forum
    Frankfurt/Main

developManagers' Transactions

  • There are no current managers’ transactions available.
  • There are no current managers’ transactions available.

developOther mandatory notifications


There are no other mandatory notifications available.
CONTACT INVESTOR RELATIONS

I look forward to your message

Do not miss any publications or news about APONTIS PHARMA AG. By registering for our IR mailings, you will always stay informed.